<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352037</url>
  </required_header>
  <id_info>
    <org_study_id>UHN-16-6058</org_study_id>
    <nct_id>NCT03352037</nct_id>
  </id_info>
  <brief_title>18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot Study</brief_title>
  <official_title>18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overlap of morphological imaging features results in many incidentally detected&#xD;
      pancreatic cystic neoplasms going undiagnosed, including benign serous cystic neoplasms (SCN)&#xD;
      and potentially malignant mucinous lesions (nonserous). The diagnostic ambiguity then lead to&#xD;
      invasive procedures such as endoscopic ultrasonography (EUS), unwarranted surgical resection&#xD;
      on SCN lesions or the need for long term periodic surveillance with delayed diagnosis of&#xD;
      potentially malignant nonserous lesions. Therefore, precise differentiation of SCN from&#xD;
      nonserous cystic neoplasms is highly desirable.&#xD;
&#xD;
      The 18F-fluorodeoxyglucose (FDG) accumulation in tumor cells, which is induced by high&#xD;
      expression of glucose transporter proteins (mainly include GLUT-1 and -3), can be used to&#xD;
      discriminate malignant and benign pancreatic cystic tumors in positron emission tomography&#xD;
      (PET) imaging. GLUT-1 expression has also been documented in benign SCN while no such&#xD;
      evidence exists in potentially malignant nonserous cystic neoplasms. Based on this evidence,&#xD;
      investigators will conduct a pilot study to evaluate if integrated 18F-FDG PET/MR imaging&#xD;
      with simultaneous MR and PET acquisition is helpful in differentiation of SCN from nonserous&#xD;
      lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigation of 18F-FDG PET/MRI efficacy in differentiating pancreatic cystic neoplasms</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Pancreatic Cystic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Patients with known pancreatic cystic lesions, including suspected pancreatic serous&#xD;
        cystic neoplasms and non-serous cystic neoplasms&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  General Contraindications to MRI such as pacemaker, brain aneurysm clip etc. -&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age below 18 years&#xD;
&#xD;
          -  Estimated GFR (eGFR &lt; 30 mL/min)&#xD;
&#xD;
          -  MRI contrast allergy;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kartik Jhaveri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

